Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Maysiglu is manufactured under GMP conditions and undergoes comprehensive testing to ensure purity and potency. This enables healthcare providers to confidently incorporate the product into therapeutic regimens.

Sitagliptin is used in the management of type 2 diabetes mellitus, either alone or as part of combination therapy.

Monotherapy: lowers HbA1c when used alone in patients inadequately controlled by diet and exercise. Combination with metformin: improves glycemic control when added to metformin in patients requiring additional therapy. Adjunct to insulin: reduces insulin dose requirements and helps achieve target glucose levels when combined with insulin therapy.

Sitagliptin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., angioedema) - Joint pain (arthralgia)

Before prescribing sitagliptin, clinicians should consider several safety factors.

Renal function: assess before initiating and adjust dose in renal impairment. Pancreatitis history: monitor for abdominal pain and discontinue if pancreatitis suspected. Hypersensitivity: discontinue at first sign of rash, swelling, or anaphylaxis. Concomitant sulfonylureas or insulin: monitor for hypoglycemia. Hepatic impairment: use with caution and monitor liver enzymes. Store at room temperature: keep in original packaging, protect from moisture and heat.

Sitagliptin can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase sitagliptin exposure. - Insulin or sulfonylureas: increased risk of hypoglycemia. - Rifampin: may reduce sitagliptin effectiveness.

Moderate Interactions (Monitor Closely): - ACE inhibitors: potential additive effect on blood pressure. - Diuretics: monitor renal function and electrolytes. - Warfarin: may affect INR, requiring monitoring.